FMTX News and Press, Forma Therapeutics Holdings Inc. From 06/11/21

Chan2545/iStock via Getty Images Forma Therapeutics ([[FMTX]] -20.9%) is trading sharply lower in morning hours after the company announced new data from its ongoing Phase 1 trial of etavopivat (formerly referred to as FT-4202) in patients with sickle cell disease ((SCD)). The resul...

Clinical results demonstrated durable improvement in hematologic and hemolytic markers, supporting the potential for improvement of red blood cell functional health in those with sickle cell disease Initial results from an open-label extension cohort showed sustained hemoglobi...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in people living with R/R AML with the IDH1 mutation Among those with CR/CRh, estimated 18-month survival is 87%; median overall survival has not yet been reached Duration of response of 13.8 ...

Forma Therapeutics Holdings, Inc. (FMTX) Q1 2021 Results Earnings Conference Call May 14, 2021, 08:00 AM ET Company Participants Mario Corso - Senior Director-Investor Relations Frank Lee - President & Chief Executive Officer Pat Kelly - Chief Medical Officer Dave Cook - Chief Scientific ...

Forma Therapeutics (FMTX): Q1 GAAP EPS of -$0.76 in-line.Cash, cash equivalents and marketable securities of $603.7M. Current cash runway is projected through the third quarter of 2024.Press Release For further details see: Forma Therapeutics EPS in-line

Development pipeline progressing to key upcoming clinical milestones Multiple-ascending dose (MAD) cohorts of FT-4202 Phase 1 trial in sickle cell disease completed; hemoglobin increased ≥ 1 g/dL in approximately 71% of patients and improved hematologic and hemolytic ma...

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release first quarter 2021 financial results on Friday, May 14, 2021. Forma management will host an investment ...

Cantor analyst Emma Nealon is maintaining her overweight rating and $68 price target on Forma Therapeutics (FMTX) despite weakness today on phase 1 results from its sickle cell candidate FT-4202.Those results indicated a lower response rate for a group treated with a 600 mg dose compared to t...

Forma Therapeutics Holdings, Inc. (FMTX) Q4 2020 Earnings Conference Call March 30, 2021 08:00 AM ET Company Participants Mario Corso - Senior Director-Investor Relations Frank Lee - President & Chief Executive Officer Patrick Kelly - Chief Medical Officer Dave Cook - Chief Scientific Off...